Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Several crosssectional and prospective studies have shown that metabolic syndrome and its
related components are associated with both prevalent and incident CKD .
Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin
remain unclear, they extend well beyond glycemic lowering, and therefore are probably best
considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes
drugs.
Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs
on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's
purpose was to observe their effects on weight control, Cardiometabolic Risk Factors,
Metabolic Syndrome risk, and diabetic nephrooathy Progression.